# Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy

> **NCT00524407** · PHASE4 · COMPLETED · sponsor: **Ortho Biotech, Inc.** · enrollment: 273 (actual)

## Conditions studied

- Chemotherapy
- Anemia
- Cancer

## Interventions

- **DRUG:** Epoetin alfa

## Key facts

- **NCT ID:** NCT00524407
- **Lead sponsor:** Ortho Biotech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-07
- **Primary completion:** —
- **Final completion:** 2002-11
- **Target enrollment:** 273 (ACTUAL)
- **Last updated:** 2010-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00524407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00524407, "Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00524407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*